Trial Profile
A Pivotal Phase III Study of RHB-204 for the Treatment of Pulmonary Nontuberculous Mycobacteria (NTM) Infections
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 29 May 2023
Price :
$35
*
At a glance
- Drugs Clarithromycin/clofazimine/rifabutin (Primary)
- Indications Nontuberculous mycobacterium infections
- Focus Registrational; Therapeutic Use
- Sponsors RedHill Biopharma
- 22 May 2023 Status changed from recruiting to discontinued, according to a RedHill Biopharma media release.
- 28 Apr 2023 According to a RedHill Biopharma media release, In August 2022, the European Commission granted Orphan Drug Designation to RHB-204, which is in an ongoing U.S. Phase 3 study, for the treatment of nontuberculous mycobacteria (NTM) disease, providing 10 years of post-approval EU market exclusivity.
- 25 Nov 2020 Status changed from planning to recruiting, according to a RedHill Biopharma media release.